Celluris is the first company in Latin America to develop personalized treatment for oncologic patients through CAR-T immunotherapy. This technique is based on the modification of the patient’s own cells that start to recognize the tumor as a target, fighting it in a precise way.
BUSINESS MODEL: B2C for oncologic patients
PRODUCT: In development
For further information, please contact us.
Back to Investors page